Crossmark

Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach

Crossref DOI link: https://doi.org/10.1007/s13555-025-01554-4

Published Online: 2025-09-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takechi, Tomoki https://orcid.org/0000-0003-1628-4979
Shimizu, Junya

Kabashima, Kenji

Ieiri, Ichiro
Funding

Funding for this research was provided by:

Maruho
License Information

Text and Data Mining valid from 2025-09-29

Version of Record valid from 2025-09-29
More Information

Article History

Received: 22 August 2025

Accepted: 17 September 2025

First Online: 29 September 2025

Declarations

:

: Tomoki Takechi and Junya Shimizu are employees of Maruho Co., Ltd. Kenji Kabashima has received consulting fees, honoraria, grant support, and/or lecture fees from AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pfizer, Procter & Gamble, Sanofi, Regeneron, Taiho, and Torii Pharmaceutical. Ichiro Ieiri has received fees from the company for consultation, lectures, and writing.

: All clinical trials included in this pooled analysis were approved by their respective independent ethics committees, and all participants provided written informed consent in accordance with the Declaration of Helsinki.

Document is current

Any future updates will be listed below